08-Nov-2021

Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial

Kazia Therapeutics Ltd's CEO Dr James Garner tells Proactive they've officially enrolled the first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021. The phase one study will focus primarily on understanding the safety, tolerability and pharmacokinetics of EVT801 across a range of doses.

26-Oct-2021

Edison TV: Kazia Therapeutics – introducing novel asset EVT-801

Kazia Therapeutics is an oncology focused drug development company based in Sydney, Australia. In addition to Kazia’s lead programme, paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway developed to treat the most common form of brain cancer, the company is developing EVT-801, a small molecule inhibitor of VEGFR3. Preclinical data have shown EVT-801 to be active against a broad range of tumor types.

20-Feb-2021

Edison TV: Kazia Therapeutics - overview and update with CEO James Garner

Kazia Therapeutics (KZA) is an oncology-focused drug development company. Its drug candidates are designed to treat diseases which are poorly served by existing therapies. In this video, James Garner, CEO, highlights the company’s business model, newest drug asset and progress over the next year.

09-Feb-2021

Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Kazia Therapeutics Ltd's Dr James Garner speaks with Proactive at the ASX Small and Mid Cap Conference. Its lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

09-Apr-2020

Kazia CEO, Dr James Garner discusses the recent positive interim data from the phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising

Kazia CEO, Dr James Garner discusses the recent positive interim data from the ongoing phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising.

12-Dec-2019

Dr James Garner discusses GBM AGILE study with Boardroom Media

Our CEO, Dr James Garner sat down with Boardroom Media to discuss Kazia joining the GBM AGILE international phase II / III study in glioblastoma with its lead program, GDC-0084.

28-Nov-2019

Dr James Garner discusses GDC-0084 interim efficacy data with Pitt Street Research

Our Chief Executive Officer, Dr James Garner, sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.

06-Sep-2019

Dr James Garner presents at the 2019 Gold Coast Investment Showcase

Our CEO, Dr James Garner recently presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase.

22-Aug-2019

Dr James Garner featured in The Australian Financial Review

Our Chief Executive Officer Dr James Garner was featured in a recent article in The Australian Financial Review on the new breed of biotechnology companies.

27-Jun-2019

Dr James Garner provides comprehensive GDC-0084 update to Morgans

Our CEO, Dr James Garner recently sat down with Morgans Senior Analyst Scott Power to provide a comprehensive update on our ongoing trials for our lead candidate, GDC-0084.

26-Jun-2019

Media coverage of DIPG researcher, Professor Matt Dun for World Brain Tumour Day

Professor Matt Dun was interviewed across leading broadcast and print media about his research into DIPG, a rare but aggressive form of childhood brain cancer.

26-Jun-2019

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase

Watch Dr James Garner's recent presentation at the Gold Coast Investment Showcase.

11-Jun-2019

World Brain Tumour Day: Enhancing awareness of the devastating childhood brain cancer, DIPG

Dr Matt Dun, a leading cancer researcher, discusses his research into Diffuse Intrinsic Pontine Glioma (DIPG) and GDC-0084.

28-May-2019

Dr James Garner discusses ground-breaking Alliance study with Boardroom Media

Our CEO, Dr James Garner sat down with Boardroom Media in Sydney to discuss Kazia’s participation in the ground-breaking study with the US National Cancer Institute-backed Alliance for Clinical Trials in Oncology for the treatment of cancer that has spread to the brain.

08-May-2019

Kazia calls for greater awareness of one of the deadliest women’s cancers worldwide

This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of one of the deadliest women’s cancers worldwide.

19-Apr-2019

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the Wholesale Investor Emergence event in Brisbane

Kazia CEO James Garner's recent presentation at the recent Wholesale Investor Emergence event in Brisbane.

02-Apr-2019

Proactive Investors speaks with Kazia CEO Dr James Garner

Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the presentation of new data from the company’s Cantrixil trial in ovarian cancer at the American Association of Cancer Research (AACR) 2019 Annual Meeting on April 1.